» Articles » PMID: 38461428

Colposcopic Findings to Study Cervical Changes in Reproductive Age Group Women Using Various Contraceptives

Overview
Date 2024 Mar 10
PMID 38461428
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colposcopy has a key role to play in see-and-treat programs for premalignant cervical lesions. The aim of the study/was to observe cervical changes with a colposcope using the Swede scoring system in fertile age group women using various contraceptives: conventional methods (barrier methods, coitus interruptus), oral contraceptives (OCPs), copper-T and bilateral tubectomy. The aim of the study was to observe and evaluate the colposcopic findings using the Swede scoring system for the diagnosis of premalignant/malignant lesions in reproductive age group women using various contraceptives.

Methods: This was a prospective observational study, conducted among 200 women of reproductive age group using various contraceptives in a tertiary care institute in North India. PAP smear, direct visual examination, VIA (Visual Inspection with Acetic Acid) examination, colposcopic examination, and (biopsy if indicated) were done. The data were collected, and analysis was done using Microsoft Excel Office Software 2019 version 19.11 and epi info (CDC Atlanta) 7.23.1. Statistical analysis was done using percentages, mean, mode, median, standard deviation, Chi-square, Fisher's Test, and Anova Test.

Results: We found positive PAP (Papanicolaou test) smears in 61.50%, positive VIA examination in 9%, and positive findings in colposcopic examination in 28.50%, Swede score of 0-3 in 100% (0-91%, 1-2%, 2-6%, and 3-1%) and positive biopsy in 9% subjects. Malignant findings were observed in 1.00% of PAP smears. Colposcopic findings were CIN 1 (cervical intraepithelial neoplasia 1) in 8.5% and CIN 2 in 0.5% subjects. Swede score was zero in 91%, 1 in 2%, 2 in 6%, and 3 in 1% of subjects. HPE (histopathological examination) was chronic cervicitis in 8.50% and mild dysplasia/CIN 1 in 0.5%. No significant statistical associations between contraceptive choice and false-positive test results or disease prevalence was found in any group except Cu-T users p = 0.0184 (especially for CIN 2; p = 0.0109 and CIN 1 more in all groups than Cu-T users). Colposcopy had sensitivity 100%, specificity 91.46% (0/0 = 0%) PPV = 5.56%, NPV = 100%, Accuracy = 91.5% for detecting mild dysplasia/CIN-non-significant (p = 0.055). Our study had mainly low-grade lesions with 100% NPV. With increase in Swede Score, sensitivity increases but at the expense of specificity but it was statistically non-significant (p = 0.055).

Conclusions: Our study may guide the rational use of colposcopy with Swede scoring for see-and-treat lesions, which is easy and with a low learning curve, as a tool for diagnosis but only in cases where indicated like unhealthy cervix because of the high rate of false-positive results. In low-grade lesions, it is highly useful to rule out the disease.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Strander B, Ellstrom-Andersson A, Franzen S, Milsom I, Radberg T . The performance of a new scoring system for colposcopy in detecting high-grade dysplasia in the uterine cervix. Acta Obstet Gynecol Scand. 2005; 84(10):1013-7. DOI: 10.1111/j.0001-6349.2005.00895.x. View

3.
Joshi S, Sankaranarayanan R, Muwonge R, Kulkarni V, Somanathan T, Divate U . Screening of cervical neoplasia in HIV-infected women in India. AIDS. 2012; 27(4):607-15. DOI: 10.1097/QAD.0b013e32835b1041. View

4.
Fahmy K, Ismail H, Sammour M, El-Tawil A, Ibrahim M . Cervical pathology with intrauterine contraceptive devices--a cyto-colpo-pathological study. Contraception. 1990; 41(3):317-22. DOI: 10.1016/0010-7824(90)90072-4. View

5.
Ajah L, Chigbu C, Ozumba B, Oguanuo T, Ezeonu P . Is there any association between hormonal contraceptives and cervical neoplasia in a poor Nigerian setting?. Onco Targets Ther. 2015; 8:1887-92. PMC: 4524589. DOI: 10.2147/OTT.S86472. View